Uniindia: Hyderabad, Dec 9 (UNI) Prestige BioPharma Limited, a Singapore-based biopharmaceutical company, and Dr. Reddy’s Laboratories Limited, an integrated pharmaceutical company on Thursday announced that they have entered into a binding agreement for an exclusive partnership for the supply and commercialization of Prestige BioPharma’s proposed trastuzumab biosimilar in select countries in Latin America and Southeast Asia.
Responding to global vaccine demand, Cytiva pledges $52 5M to build South Korean factory fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
The LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight | MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, and Others
iCrowd Newswire
DelveInsight s
LAG-3-Next Generation Immunotherapy market size, trends, emerging therapies, technological innovations, market barriers, market drivers, ongoing
LAG-3-Next Generation Immunotherapy clinical trials, key pharmaceutical companies, collaboration in the space, and actively pushing the growth of
LAG-3-Next Generation Immunotherapy market size forward in the 7MM [US, EU5(France, Germany, the United Kingdom, Spain, and Italy) and Japan].
Key facts of the are:
According to Delveinsight, the market is anticipated to show positive growth due to the launch of upcoming therapies in the LAG-3 Next Generation target during the forecast period 2022–2035. Moreover, the US will occupy the maximum market share in the overall market size in 2035.